BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: DBV Technologies (Paris:DBV) (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the appointment of Mr. Stef Koppelman, PhD as General Scientific Advisor. As such, Stef will champion DBV’s research efforts and provide the Executive Committee with key advice and insight, notably on food allergens and scientific matters.